Explore the words cloud of the SLAM-Dx project. It provides you a very rough idea of what is the project "SLAM-Dx" about.
The following table provides information about the project.
FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH
|Coordinator Country||Austria [AT]|
|Total cost||150˙000 €|
|EC max contribution||150˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2019-10-01 to 2021-03-31|
Take a look of project's partnership.
|1||FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH||AT (WIEN)||coordinator||150˙000.00|
One of the greatest challenges today is to select the right drug for the right patient at the right time. A lack of diagnostic tools for predicting therapy response currently hampers patient-tailored treatment decisions in the clinic with severe implications for economy and – most importantly – patient survival.
Profiling transcriptional responses to drug treatment is a key method for probing the activity of targeted therapeutics and guiding their use in the clinic. A major limitation of established gene expression profiling techniques (such as microarrays and RNA-seq) is their limited time resolution precluding the distinction of direct from secondary transcriptional responses to drug therapy. This hampers their utility for deciphering drug action and guiding patient-tailored treatment decisions.
To overcome this problem, as part of an ERC-StG project (Systematic in-vivo analysis of chromatin-associated targets in leukemia, 336860) I have co-developed thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAMseq) as a rapid, robust and highly scalable method for the unbiased quantification of changes in mRNA production upon cell perturbations. Its unique features (low input cell numbers, short treatment-to-sample time, 1-day protocol library preparation in 96-well format) may qualify SLAMseq as the first method to probe the function, efficacy and selectivity of candidate therapeutics in primary (tumor) cells with unprecedented precision and on a large scale.
In this ERC-PoC project, I propose to establish technical and commercial proof-of-concept for SLAMseq’s application in preclinical and clinical drug development and optimization, and for patient-tailored treatment selection. Upon the successful proof-of-concept for SLAMseq’s application as diagnostic tool, SLAM-Dx has the potential to revolutionize translational research and personalised medicine in a variety of disease areas.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SLAM-DX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SLAM-DX" are provided by the European Opendata Portal: CORDIS opendata.